The SYT-SSXI and SYT-SSX2 fusion genes, derived by reciprocal translocations t(X;18), are acquired genetic events strongly associated with the tumorigenesis of synovial sarcoma. In approaching the mechanisms underlying the formation of these fusion oncogenes, we have analysed the genomic sequences surrounding the SYT-SSX breakpoints in 10 tumors, two expressing SYT-SSXI and eight expressing SYT-SSX2 fusion transcripts. The breakpoints were found to be clustered in the 5 0 end of intron 10 of SYT, and in two cluster regions within intron 4 of SSX2, whereas the two breakpoints in SSX1 intron 4 were 0.5 kb apart. SYT intron 10 is abundant in repetitive regions with the interspersed repeats occupying 66% of the whole intron. Nine of the 10 breakpoints in intron 10 of SYT and six of the eight breakpoints in intron 4 of SSX2 were at or near repetitive regions. These findings suggest that repetitive regions may contribute to the distribution of genomic breakpoints. Several of the fusion sequences exhibited characteristic signs of nonhomologous end joining, including microhomologies at the end points as well as deletions. Sequences highly homologous (83-94%) to consensus topoisomerase II cleavage sites were identified at or near the breakpoints in all 10 tumors, suggesting a role of this enzyme in creating staggered ends at the breakpoint. Furthermore, sequences highly homologous to consensus Translin binding sequences were found at the breakpoints in two cases, and an Alu-Alu fusion and an insertion of a 206-bp LINE-1 element were found at the breakpoint in one case each. The demonstration of characteristic sequences at the SYT-SSX breakpoint regions is expected to improve our understanding of the molecular genetic mechanisms behind translocations in general, and of the SYT-SSX fusions in synovial sarcoma in particular.
Introduction
The importance of chromosomal translocations in human cancer is becoming increasingly recognized. Today, the identification of the fusion genes involved has implications for both diagnostic, prognostic and therapeutic purposes (Ladanyi, 1995; Sorensen and Triche, 1996) . Detailed characterization of the translocations has also provided insight into the pathophysiology of these tumors by virtue of the biological effects of their fusion gene products (Rabbitts, 1994; Sreekantaiah et al., 1994) . However, the initial causes of the translocations and the molecular mechanisms involved in illegitimate recombination are largely unknown. Analyses of DNA sequences located in the vicinity of chromosomal translocation breakpoints, in some kinds of tumors, have suggested that homologous recombination and/or site-specific recombinogenic sequences may be involved. These include, for example, heptamer/ nonamer sequences, Translin consensus sequences, topoisomerase I and II clevage sequences, chi-consensus sequences, Alu repeats, palindromic sequences, alternating purine/pyrimidine and polypurine or polypyrimidine sequences (Bullock et al., 1985; Finger et al., 1986; Krowezynska et al., 1986; Nicholls et al., 1987; Boehm et al., 1989; Chen et al., 1989; Sperry et al., 1989; Camerini-Otero and Hsieh, 1993; Aoki et al., 1995; Broeker et al., 1996) .
Synovial sarcomas constitute a group of highly malignant soft tissue tumors, typically arising in the para-articular regions of children and young adults. Biphasic and monophasic subtypes can be distinguished based on morphological characteristics (Weiss and Goldblum, 2001) . Cytogenetic analyses of synovial sarcomas have revealed a characteristic chromosomal translocation, t(X;18)(p11.2;q11.2), which can be seen in more than 90% of both tumor subtypes (Sreekantaiah et al., 1994) . The presence of this translocation as the sole cytogenetic abnormality in some tumors, indicates that it may play a key role in tumor development. Cloning of the translocation breakpoints showed that the SYT gene at 18q11 is fused to a member of the SSX gene family, all located at Xp11, resulting in the generation of either an SYT-SSXI, an SYT-SSX2, or rarely an SYT-SSX4 fusion gene (Clark et al., 1994; Crew et al., 1995; de Leeuw et al., 1995; Skytting et al., 1999) . The resulting fusion transcripts are highly similar between tumors, being consituted almost invariably of exons 5-6 of SSX fused in frame after exons 1-10 of SYT. Similar to other fusion oncogenes in sarcomas, SYT-SSX leads to the expression of a chimeric protein that is believed to deregulate the transcription of specific target genes (Ladanyi, 1995; Triche in Sorensen and Triche, 1996) . In spite of the numerous and detailed analyses of the SYT-SSX fusion transcripts, their detection and possible involvement in tumor development, the associated genomic breakpoint sequences and the mechanisms by which this translocation occur remain largely unknown. As a step towards exploring these questions, we have characterized the genomic breakpoint regions in 10 cases of synovial sarcomas which express either an SYT-SSX1 or SYT-SSX2 fusion transcript.
Results
In this study, the genomic sequences surrounding the translocation breakpoints were determined in 10 synovial sarcomas: two expressed an SYT-SSX1 and eight expressed an SYT-SSX2 fusion transcript. The result are shown in Table 1 and Figures 1-3 .
Analyses of the normal intron sequences of SYT, SSX1 and SSX2 Figure 1 illustrates the normal SYT, SSX1 and SSX2 genes together with the formation of the SYT-SSX fusion genes. In all 10 tumors studied here, the generation of SYT-SSX involved genomic breaks in intron 10 of SYT, and intron 4 of SSX1 or SSX2 (Figure 2) . By bioinformatic analyses, the wild-type intron 10 of SYT was shown to be abundant in repetitive regions (direct or inverted) including short interspersed elements (SINEs), long interspersed elements (LINEs) and DNA elements. In total, there are four Alus, four SINEs, five LINE-1s, five LINE-2s and one DNA element within intron 10 of the SYT gene, with approximately 66% (9260 bp) of the entire intronic region being composed of interspersed repeats. Intron 4 of SSX1 contains two SINEs and one Alu, which occupy a region of 462 bp (23%) of the whole intron. In intron 4 of SSX2, three SINEs and one Alu occupy a 475 bp region (24%) of the intron.
Genomic breakpoints in synovial sarcomas with SYT-SSX1 or SYT-SSX2 fusion
The SYT-SSX1 genomic fusion fragments were successfully amplified in two synovial sarcomas (cases 1 and 2), while in the other eight tumors (cases 3-10) the SYT-SSX2 genomic sequences were amplified ( Figure 2 , Table 1 ). The sequences have previously been submitted to GenBank (accession numbers AF404831, AF404832, AF500624 and AY138487-AY138495). All of the Table 1 ). In nine tumors, the breakpoint in SYT intron 10 was found to be in LINEs (cases 2, 6, 8, 9 and 10) or adjacent to LINEs (cases 1, 4, 5 and 7), the exception being tumor 3 in which a LINE-2 element was found 240 bp away from the breakpoint (Table 1 ). In the case of SSX1 and SSX2, all of the breakpoints were found in intron 4. In the two tumors with SYT-SSX1 genomic fusion fragments (cases 1 and 2), the breakpoints in SSX1 were at different locations, being separated by approximately 0.5 kb (Figure 1 ). Neither of these two breakpoints occured in or around repeat sequences (Table 1) . The breakpoints indentified in SSX2 clustered at the 5 0 and 3 0 ends of intron 4 ( Figure 1 , Table 1 ). Five tumors had breakpoints arising in an approximately 0.4 kb region at the 5 0 -end (cases 3, 4, 5, 6 and 9) and three tumors showed breakpoints in a 0.4 kb 3 0 -region (cases 7, 8 and 10). In one of the eight tumors, the SSX2 breakpoint occured in a SINE element (case 9), while in five tumors the breakpoints were near SINE elements (cases 4, 5, 6, 8 and 10) . No repetitive elements were found to be localized to or around the SSX2 breakpoints in tumors 3 and 7. Taken together, there was one tumor with both SYT and SSX breakpoints in repetitive elements (case 9), five tumors with both SYT and SSX2 breakpoints in or near repetitive elements (cases 4, 5, 6, 8 and 10), three tumors with either SYT or SSX breakpoints in or near repetitive elements (cases 1, 2 and 7), and one tumor in which none of the SYT and SSX breakpoints was in or near repetitive elements (case 3).
Genomic alterations associated with the SYT-SSX1 and SYT-SSX2 gene fusions
To define exactly the genomic breakpoints, the sequences of both the SYT-SSX and the SSX-SYT should be determined. Here the reciprocal fusion gene was identified in four of the 10 tumors studied, including SSX1-SYT in one tumor and SSX2-SYT in three tumors (Table 1 , Figure 3) . Ten of the 14 fusion genes for which both original sequences are known had regions of microhomology at the breakpoint of between 1 and 7 bp (71%). Of the tumors where both forward and reciprocal sequences were determined (cases 2, 4, 6 and 10), there was no tumor with a simple end-to-end reciprocal translocation. Instead, all of these four tumors had associated genomic alterations constituting of SYT and SSX deletions ranging from 13 to 172 bp ( Figure 3) . In case 4, deletions of 13-20 and 113-120 bp from the SYT and SSX2 genes, respectively, were observed ( Figure 3) . Interestingly, cases 4 and 5 exhibited identical SYT-SSX2 genomic fusion sequences. Therefore, the uniqueness of tumors 4 and 5 was confirmed by genotyping of four microsatellite markers, which demonstrated distinctly different genotypes for the two tumor DNAs. In addition to this, a 7 bp microhomology (CACATTT) between SYT and SSX2 was revealed at the breakpoints of SYT-SSX2 in cases 4 and 5. In both the SYT and SSX2 locus, this CACATTT region was within sequences which showed a high degree of similarity to consensus topoisomerase II cleavage sites (83% in both genes; Table 1, Figure 3 ). As the reciprocal sequence, SSX2-SYT, was not able to be amplified in case 5, it cannot be determined whether these two cases also have the same SSX2-SYT genomic fusion sequences.
In case 6, 21-22 and 37-38 bp were deleted from the SYT and SSX2 genes, respectively. At the breakpoint of SYT-SSX2, a 6 bp microhomology sequence (GAAAGC) was present in both the SYT and SSX2 genomic sequences. Furthermore, sequences homologous to consensus topoisomerase II cleavage sites (87% in both genes) were found at the SYT and near the SSX2 breakpoints (Table 1, Figure 3) .
In case 2, the SYT and SSX1 genes were deleted with 58-61 and 75-78 bp, respectively. Sequences with 89% homology to consensus topoisomerase II cleavage sites were found at the breakpoint of both the SYT and SSX1 genes. In addition, a sequence of 18 bp was present in the 75-78 bp deleted fragment of SSX1, which showed a high homology (94%) to the consensus topoisomerase II cleavage site (Figure 3, Table 1 ). Another finding was that the SYT breakpoint in tumor 2 was close to that in tumor 6, located only 5 bp away for the reciprocal breakpoint and 43 bp away for the forward breakpoint.
In case 10, sequences of 172-173 and 76-77 bp were deleted from the SYT and SSX2 genes, respectively. Computer analysis of the SSX2-SYT fusion gene revealed that both breakpoints within SYT and SSX2 occurred in Alu sequences (Alu Sc). This is the only case in which the fusion gene was associated with the fusion of two Alu sequences. Sequences with high homology (89 and 83%) to consensus topoisomerase II cleavage sites were also found at or near the breakpoint of the SYT and SSX2 genes. The deleted fragment of SSX2, contained an 18 bp sequence with high homology (89%) to the consensus topoisomerase II cleavage site (Figure 3 , Table 1 ).
In case 1, a 206 bp insertion was observed between the breakpoints in the SYT-SSX1 fusion gene. The sequence of this inserted fragment is identical to the sequence of SYT, starting 8587 bp downstream of the breakpoint. Computer analysis revealed that this fragment is highly homologous to a LINE-1 element. This is the only case in which a LINE-1 element insertion was observed. Around the breakpoints of SYT and SSX1, sequences with high homology to consensus topoisomerase II cleavage sites were found in this case (Table 1) .
In the other four tumors (cases 3, 7, 8 and 9), sequences highly homologous to consensus topoisomerase II cleavage sites were also found at, or near, breakpoints in both the SYT and SSX2 genes ( Table 1) . The positions of other recombination sequences (heptamer/nonamer, chi consensus, alternating purine/pyrimidine, polypurine or polypyrimidine sequences) were not correlated with those of the junction points. However, using criteria similar to Hosaka et al. (2000) , we found that the sense sequence at the SYT breakpoint in tumor 3 and the antisense sequence at the SSX1 breakpoint in tumor 2 (Figure 3 ) had a strong homology (71 and 75%, respectively) to the consensus recognition sequences of Translin.
Discussion
Various mechanisms have been implied in the generation of chromosomal translocations in malignancies. The IG/TCR recombination system has been shown to be involved in some lymphoid neoplasms, while in some other tumor types, various promoting sequences have been suggested to play a role in the mechanism that mediates chromosomal translocation. These promoting sequences include consensus sequences, such as Translin, topoisomerase I an II, chi, Alu sequences, palindromic sequences, alternating purine/pyrimidine and polypurine or polypyrimidine sequences (Bullock et al., 1985; Krowezynska et al., 1986; Nicholls et al., 1987; Boehm et al., 1989; Chen et al., 1989; Sperry et al., 1989; Camerini-Otero and Hsieh, 1993; Aoki et al., 1995; Broeker et al., 1996) .
Chromosomal translocations can be found in many types of solid tumors especially in sarcomas. Some features, including Translin recognition sites, topoisomerase II cleavage sites, Alu repeats, palindromic sequences and other characteristic motifs, have been identified near the genomic breakpoints in alveolar rhabdomyosarcoma, myxoid liposarcoma and some cases of Ewing's sarcoma (Chalk et al., 1997; Panagopoulos et al., 1997; Barr et al., 1998; Ishida et al., 1998; Kanoe et al., 1999) . Although progress on the diagnostic utilities and functions of the SYT-SSX fusion gene in synovial sarcomas has been made in recent years, studies concerning the mechanisms underlying the t(X;18) chromosomal translocation have not, to our knowledge, been reported. We analysed the genomic breakpoint sequences of SYT-SSX in 10 cases of synovial sarcoma to investigate whether there were some features of DNA sequence and/or chromatin structure that may be involved in the translocation process, and whether some sequence motifs may be directly involved in determining the site of these breakpoints. The abundance of repetitive regions in intron 10 of the SYT gene (66%) suggests that the increased frequency of breakpoints in this intron may relate to this abundance. Analysis of other SYT introns showed a decrease in repetitive regions when compared to intron 10. For example, intron 7 of the SYT gene is 13,168bp long, comparable with intron 10(14 019 bp), but the repetitive regions in intron 7 accounted for only 41% of the whole intron and this per cent was the largest in other introns except intron 10. We also found that nine of 10 breakpoints in intron 10 were at or near repetitive regions. These results suggest that repetitive regions may contribute to the distribution of genomic breakpoints in intron 10 of the SYT gene. It is likely that abundance of repetitive regions in intron 10 of the SYT gene may make this intron more prone to recombination events, and the distribution of these repetitive regions may, to some extent, determine the distribution of the breakpoints. The distribution of breakpoints in intron 4 of SSX2 may also be attributed to the structure of this intron. Six of eight breakpoints (75%) were at or adjacent to repetitive regions (SINEs). Similar results have been reported in translocation breakpoints of the Philadelphia chromosome (Toth and Jurka, 1994) . As for the SSX1 gene, however, we could not draw such a conclusion because neither of the two breakpoints occurred at or near repetitive regions. It is possible, in these cases, that other mechanistic factors may be involved in the chromosomal translocation process.
To investigate whether there were characteristic sequence motifs surrounding the breakpoints in the 10 synovial sarcomas, the precise breakpoint sequence needed to be defined. We successfully amplified the genomic breakpoints of both the SYT-SSX and the reciprocal SSX-SYT fusion genes in four of the 10 synovial sarcomas. Detailed sequence analyses revealed that there was no case of simple end-to-end translocations, and deletions ranging from 13 to 172 bp accompanied each of the translocations. Gain and loss of genetic material around the breakpoints have also been observed in chromosomal translocations in liposarcomas and Ewing's sarcomas (Zucman-Rossi et al., 1998; Kanoe et al., 1999) . These results suggested that a nuclease(s) involved in generating the translocation makes staggered cuts in the DNA strands followed by either deletion or DNA synthesis to fill the gap.
The common feature of the 10 synovial sarcoma cases investigated in this study was the presence of sequences homologous to consensus topoisomerase II cleavage sites, at or near the breakpoints in both the SYT and SSX genes. Interestingly, two cases of synovial sarcoma exhibited the same SYT-SSX2 fusion breakpoints. The prominent finding in these two cases was the presence of a microhomology of 7 bp (CACATTT) at the fusion point of SYT-SSX2 and this 7 bp sequence was found to be a component of sequences homologous (both 83%) to consensus topoisomerase II cleavage sites in the two genes involved. These results suggest a strong association of topoisomerase II and the translocation breakpoints. Similar findings have been reported in liposarcomas and, more commonly, in leukemias (Broeker et al., 1996; Kanoe et al., 1999; Zhang et al., 2002) . Recently, near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites were found at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia (Lovett et al., 2001) . DNA topoisomerase II catalyzes the relaxation of supercoiled DNA by transiently cleaving and religating both strands of the double helix. Our results suggested the importance of toposoisomerase II as an endonuclease in the process of creating staggered double-strand cut ends. Owing to the looseness of consensus sequences for topoisomerase II cleavage sites, in vivo binding experiments are needed to confirm the involvement of topoisomerase II in the development of translocations.
Another factor that may be involved in the process of translocations is Translin. In two tumors (cases 2 and 3), the breakpoint sequence showed strong homology to the consensus binding site sequence of Translin. Translin is a protein involved in recombination and translocations, as it not only binds to translocation breakpoint sequences in hematopoietic malignancies but also binds to translocation breakpoints in alveolar rhabdomyosarcomas and liposarcomas (Aoki et al., 1995; Chalk et al., 1997; Hosaka et al., 2000) . The degress of homology to consensus Translin-binding sites observed in this study (71 and 75%, respectively) was in accordance to those reported previously in liposarcomas (more than 70%), but higher than those reported in alveolar rhabdomyosarcomas (62%). Absence of sequences highly homologous to consensus Translin-binding sites at genomic breakpoints in the other eight cases, however, suggests that Translin is not likely to play a major role in the translocation process in synovial sarcomas.
Alu-mediated homologous recombination has been reported in many types of tumors (Chen et al., 1989; Sowerby et al., 1993; Kolomietz et al., 2002) . In one tumor (case 10), we found an Alu-Alu fusion in the reciprocal SSX2-SYT gene. This may suggest an Alu element-mediated homologous recombination mechanism, or it may also indicate that the presence of Alu repeats may predispose these regions to rearrangements by the formation of loop structures. It is unlikely, however, that Alu sequences play a key role in the determination of breakpoints, as Alu sequences were not detected at the breakpoints in any of the other synovial sarcomas in this study.
An insertion of a 206 bp homologous DNA segment from intron 10 of the SYT gene showing sequence homology to a LINE-1 element was found at the breakpoint in case 1. The significance of this insertion is not known, however, it may suggest a transposition during the translocation process. A similar finding was reported in desmoplastic small round cell tumor with a 480 bp heterologous DNA segment with homology to the LINE-1 DNA consensus sequence inserted at the genomic breakpoint (Liu et al., 1997) .
In conclusion, characteristic sequence motifs at the SYT and SSX breakpoint regions, identified in all synovial sarcomas in this study, support the involvement of the repetitive regions and consensus topoisomerase II cleavage sites in the translocation process.
Materials and methods

Tumor samples
Ten cases of primary synovial sarcoma were analysed in this study. Two tumors (cases 2 and 10) were obtained at the Fundan University Cancer Hospital, Shanghai, People's Republic of China, and the other eight cases were from the Karolinska Hospital, Stockholm, Sweden. All tumor tissue samples used for DNA and RNA analyses were collected in direct connection to surgery, snap-frozen in liquid nitrogen, and stored at À801C until use. The diagnoses of synovial sarcoma were established by histopathological and immunostaining analyses of the routine paraffin-embedded samples according to established criteria (Weiss and Goldblum, 2001) . The presence of a SYT-SSX1 or SYT-SSX2 fusion transcript in these 10 synovial sarcomas was determined by RT-PCR screening for the respective fusions and subsequent sequence analysis as described previously . This showed that two tumors (cases 1 and 2), expressed SYT-SSX1 fusion transcripts, while the other eight tumors expressed SYT-SSX2 fusion transcripts. Sequencing of the RT-PCR products showed that exon 10 of SYT was linked, in frame, to exon 5 of SSX1 or SSX2, forming a 5 0 -SYT-SSX1-3 0 or 5 0 -SYT-SSX2-3 0 fusion transcript.
DNA isolation and genomic long-distance PCR
High molecular weight DNA was extracted from the tumor samples using a standard method with Proteinase K digestion and phenol-chloroform extraction (Sambrook et al., 1989) . Partial genomic sequences for the SYT gene were aligned with published cDNA sequences (Clark et al., 1994) in order to identify the 14 019 bp intron 10 (SYT, g.373658-387676, accession number NT_010990) where the genomic breaks are likely to occur. At the genomic level, both the SSX1 and SSX2 genes are expected to break within intron 4 (SSX1, g.251249-253221 and SSX2, g.140996-142993, accession number NT_025348). Genomic long-distance PCR was used to amplify SYT-SSX1 and SYT-SSX2 fusion genes using the following primers: the SYT forward primer (5 0 -CCAGCAGAGGCCT-TATGGATA-3 0 , exon 10) plus the SSX1 reverse primer (5 0 -GTGCAGTTGTTTCCCATCG-3 0 , exon 5) or the SSX2 reverse primer (5 0 -GCACAGCTCTTTCCCATCA-3 0 , exon 5). In order to amplify the reciprocal fusion genes, the following primers were used: DFX1 (5 0 -CAACTTATGTAG-CACCGACG-3 0 , intron 4 of SSX1) plus DRT1 (5 0 -AAAGTT-CAAGTCCCCTAATACG-3 0 , intron 10 of SYT) for SSX1-SYT, and DFX2-1 (5 0 -GTCCTCAGATGACTTTCGGC-3 0 , intron 4 of SSX2), DFX2-2 (5 0 -TCATAAAAATACAA-AACTTAGCG-3 0 , intron 4 of SSX2) plus DRT2 (5 0 -CTGGGCA-TGGTAGCGCAC-3 0 , intron 10 of SYT) for SSX2-SYT. The PCR was performed using 0.5 mg of genomic DNA as template in 25 ml reactions containing 2.5 ml of LAPCR buffer, 2.5 mm MgCl 2 , 0.4 mm of each dNTP, 1.25 units TaKaRaLA Taq (TaKaRa, Shiga, Japan) and 0.4 mM of each of the forward and reverse primers. The amplifications were performed using a 480 DNA Thermal Cycler(Applied Biosystems, Perkin-Elmer Corp., Foster City, CA, USA) with the following thermocycling conditions: an initital denaturation at 941C for 2 min, followed by 35 setp cycles of denaturing at 941C for 30 s, annealing at 581C for 1 min, and extension at 721C for 5 min, followed by a final extension at 721C for 10 min. The amplified products were analysed by electrophoresis in 0.9% agarose gels, from which the bands were cut and purified with a QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Direct sequencing was performed applying the 'primer walking' method. Sequencing reactions were carried out using the BigDye Terminator Cycle Sequencing Ready Reaction Mix (Applied Biosystems) and analysed on an ABI PRISM 310 genetic analyzer (Applied Biosystems).
